Zambon acquires Breath Therapeutics for up to £446m
Under the deal, Zambon has made an upfront payment of €140m (£125m) to acquire Breath Therapeutics and its subsidiaries and the acquisition value could increase to €500m (£446m)
Superluminal Medicines secured $120m in a Series A funding round to advance the development of its assets into clinical trials.
Ruxience, a monoclonal antibody (mAb), has been approved to treat non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Ruxience works
A total of 396 patients with moderate-to-severe psychotic symptoms were randomized to receive either pimavanserin or placebo added to their current antipsychotic treatment. There is currently no FDA-approved